The Impact of Person Centred Care (PCC) in Grave's Disease

Status Recruiting

Clinical Trial Summary

Mental fatigue (MF) is prevalent after Graves' disease (GD), which is the most common form of hyperthyroidism. We have reported that 38% of patients, compared to 11% of control subjects, suffer from MF more than 1 year after successfully reversing of their hyperthyroidism and that MF is an entity of its own, separated from MF combined with anxiety or depression. The brain pathophysiology is unknown and there is no medical treatment, which requires patients to simply adapt to the situation. In the new national guideline for hyperthyroidism (Jan 2023), rehabilitation is recommended, but currently rarely offered to these patients. The problem is significant for patients, as illustrated by frequent media appeals. In this project, we hypothesise that person-centred care (PCC), which promotes positive coping strategies and increases self-efficacy by engaging patients as partners in their own care, improves MF, reduces sick leave, and lowers the recurrence rate of GD. In two work packages (WP), we will: WP1 Evaluate the effect of PCC eHealth intervention (telephone and digital platform) as an add-on to usual care vs usual care alone in a randomized controlled trial (RCT) of 220 patients on self-efficacy, days of sick-leave (composite score as primary outcome), MF, recurrence rate of disease, coping strategies, perceived stress, quality of life (QoL) and personality. WP2 Investigate the cost-effectiveness of the intervention Patients with GD have impaired long-term QoL. PCC could improve long-term outcomes of this autoimmune disease and may apply to other patient groups. This is in line with the societal aim to reduce mental illness.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Graves Disease

Clinical Trial Details

NCT number	NCT06309316
Study type	Interventional
Source	Vastra Gotaland Region
Contact	Agneta Lindo
Phone	+46766185481
Email	agneta.lindo@vgregion.se
Status	Recruiting
Phase	N/A
Start date	March 25, 2024
Completion date	December 30, 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05774535` - Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
Completed	`NCT02973802` - ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy	Phase 1
Completed	`NCT02491567` - DNA Methylation and Autoimmune Thyroid Diseases
Terminated	`NCT01320813` - Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy	N/A
Completed	`NCT00432146` - Effect of Lugol's Solution in the Patients With Graves' Disease	N/A
Recruiting	`NCT06081439` - Validating Immunological Markers Associated With Mental Fatigue in Graves' Disease
Not yet recruiting	`NCT06327828` - Methimazole in Graves' Disease - Comparing the Computer-aided Treatment DigiThy Versus Usual Care	N/A
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT01727973` - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy	Phase 1/Phase 2
Active, not recruiting	`NCT04135573` - The Relationship Between NK Cell and Graves' Disease
Recruiting	`NCT06134219` - Course for Brain Fatigue After Graves' Disease Controlled Study	N/A
Completed	`NCT04239521` - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting	`NCT05678374` - Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
Completed	`NCT03009357` - Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis
Recruiting	`NCT05510609` - Three-dimensional Ultrasonography Thyroid Volume Measurement.	N/A
Not yet recruiting	`NCT06426758` - Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation
Recruiting	`NCT05907668` - A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease	Phase 2
Recruiting	`NCT06275373` - The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Recruiting	`NCT03303053` - Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism	Phase 3
Recruiting	`NCT05461820` - Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease	Phase 4